SCWorx wins Nasdaq relisting after near-delisting crisis

SCWorx Corp., a Massachusetts-based provider of data management solutions to healthcare supply chains, has narrowly avoided delisting from the Nasdaq Capital Market after the exchange's Hearings Panel reversed its September 2026 decision to remove the company's common stock from trading.

The Panel's October 2 ruling confirmed that SCWorx now meets both the minimum bid price requirement and the minimum publicly held shares threshold under Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4). Trading in the company's stock, suspended since 14 April 2026, is expected to resume on a date yet to be confirmed by Nasdaq. In the interim, shares continue to trade on the OTCQB Venture Market under the ticker WORX.

How SCWorx pulled back from the edge

The turnaround hinged on a private placement completed on 16 September 2026. Combined with the exercise of outstanding warrants, the transaction pushed SCWorx's publicly held shares to 549,092, clearing the 500,000-share floor by a margin of roughly 10%. The company's closing bid price has held at or above $1.00 per share on every trading day since 4 August 2026, including the ten consecutive sessions following 17 September required under Nasdaq rules.

The Panel has not, however, granted an unconditional reprieve. SCWorx is now subject to a Discretionary Panel Monitor running until October 2027, during which it must submit monthly reports covering shares outstanding, insider holdings, and public float. Critically, if Nasdaq determines the company has breached any continued listing standard during that window, it will receive no opportunity to submit a compliance plan or cure period before a delisting determination is issued. The company would retain the right to appeal, but the procedural safety net available to most listed companies would not apply.

A further condition required each investor in the September placement to confirm in writing that it would not invoke its contractual right to terminate its purchase based on the Panel's initial September delisting decision. Those agreements have been delivered, removing one near-term uncertainty, though forward-looking risks remain material, as the company itself acknowledges in its SEC filing.

"We are pleased that the Panel has recognised the steps the Company has taken to regain compliance with Nasdaq's listing requirements and look forward to the resumption of trading on Nasdaq," said Tim Hannibal, SCWorx's chief executive.

The wider signal for micro-cap health-data firms

SCWorx's situation is a textbook illustration of the liquidity and governance pressures facing small-cap companies in the healthcare data sector. The company's core business, standardising item master and supply-chain data for healthcare providers, addresses a genuine operational gap. Hospital supply-chain data remains notoriously fragmented, and the sector has attracted growing interest from both strategic acquirers and digital health investors seeking interoperability plays.

Yet SCWorx's near-exit from Nasdaq also reflects a broader structural tension: the compliance burden imposed by US public markets sits heavily on micro-cap companies whose revenue base and public float may not justify the overhead. For investors allocating across healthcare IT, this episode is a reminder that the segment's most interesting assets are often the most exposed to exchange compliance risk, particularly in the period between a growth pivot and meaningful revenue scale. The one-year monitoring regime now in place will serve as a real-time stress test of whether SCWorx can stabilise its capital structure while executing on its product roadmap.